Piper Sandler analyst David Amsellem raised the firm’s price target on AbbVie (ABBV) to $289 from $284 and keeps an Overweight rating on the shares following quarterly results. The firm cites higher Skyrizi estimates in 2026-plus and higher estimates for key products in the Neuroscience segment, which it believes remains a largely under-the-radar business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: